Neuroblastoma
483
74
109
236
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
71 trials with published results (15%)
Research Maturity
236 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.6%
51 terminated out of 483 trials
82.2%
-4.3% vs benchmark
6%
31 trials in Phase 3/4
30%
71 of 236 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 236 completed trials
Clinical Trials (483)
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy